Table 4.
SPID values at other times/intervals, by analysis method (LS mean and SE)
| Analysis method and SPID interval | Meloxicam IV 30 mg (n=20) | Meloxicam IV 60 mg (n=20) | Placebo (n=19) |
|---|---|---|---|
| W2LOCF | |||
| SPID6 | −793.87 (172.45)* | −663.17 (172.64)* | 146.22 (176.91) |
| SPID12 | −1655.1 (338.78)* | −1334.9 (339.15)* | 319.67 (347.53) |
| SPID24 | −3024.0 (644.63)* | −2793.3 (645.34)* | 276.46 (661.28) |
| SPID12–24 | −1368.9 (343.34)* | −1458.4 (343.72)* | −43.21 (352.21) |
| SPID12–48 | −7586.8 (1121.12)* | −7015.7 (1122.35)* | −2311.0 (1150.07) |
| SPID24–48 | −6217.9 (817.22)* | −5557.3 (818.12)* | −2267.8 (838.33) |
| LOCF | |||
| SPID6 | −328.52 (170.37)# | −413.68 (70.56)* | 277.92 (174.77) |
| SPID12 | −448.14 (296.78)* | −475.49 (297.11)* | 761.69 (304.45) |
| SPID24 | −637.70 (559.56)* | −552.40 (560.18)* | 1727.51 (574.01) |
| SPID12–24 | −189.56 (272.90)* | −76.91 (273.20)# | 965.82 (279.95) |
| SPID12–48 | −573.80 (835.66)* | −298.37 (836.58)* | 2906.44 (857.24) |
| SPID24–48 | −384.24 (563.22)* | −221.46 (563.84)* | 1940.62 (577.76) |
Notes:
*
P≤0.01 versus placebo;
#
P≤0.05 versus placebo.
Abbreviations: LOCF, last observation carried forward; LS, least-squares; SE, standard error; SPID, summed pain intensity differences; W2LOCF, 2-hour windowed last observation carried forward.